Eli Lilly and Company (LLY) — closed signal from March 27, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on June 25, 2026.
Predicted vs. what happened
LLY price · publication thesis → realized outcomesplit-adjusted
$880.00 – $910.00Entry zone — fair-value band
$897.99Published — price the day we called it
$1,041.67Target — the price the thesis aimed for
$1,182.73Peak — highest point inside the window, not a realized return
$1,127.69Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 55 days.
Peak price
$1,182.73
peak on June 8, 2026 — not a realized returnPeak gain
+31.7%
peak, from the publication priceWindow close
$1,127.69
end-of-window price, context onlyDays to target
55
Window
March 27, 2026 – June 25, 2026
The thesis — published March 27, 2026
Predicted growth
+16%
over the measurement windowTarget price
$1,041.67
the price the thesis aimed forEntry zone
$880.00 – $910.00
the fair-value band we waited forPrice at publication
$897.99
published March 27, 2026Confidence
80%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Lilly is a big drug company with steady sales and strong recent performance. A recent price dip makes it more attractive because its main businesses-diabetes, obesity, and immunology-are performing well and new EBGLYSS durability data expands confidence beyond just obesity. Health stocks often hold up when markets wobble, and Lilly still shows reliable earnings strength.
Primary drivers
- Clear leadership in diabetes and obesity treatments
- Reliable earnings and operational execution
- New EBGLYSS data extends clinical momentum
- Healthcare stocks often hold up in volatile markets
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.